Editorial European Journal of Nuclear Medicine and Molecular Imaging

[1]  K. Rahbar,et al.  Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Jinming Yu,et al.  Can an 18F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma? , 2016, The Journal of Nuclear Medicine.

[3]  Q. Xie,et al.  First Experience of 18F-Alfatide in Lung Cancer Patients Using a New Lyophilized Kit for Rapid Radiofluorination , 2013, The Journal of Nuclear Medicine.

[4]  Lixin Lang,et al.  Quantitative Analysis and Comparison Study of [18F]AlF-NOTA-PRGD2, [18F]FPPRGD2 and [68Ga]Ga-NOTA-PRGD2 Using a Reference Tissue Model , 2012, PloS one.

[5]  Xiaoyuan Chen,et al.  Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. , 2011, Bioconjugate chemistry.

[6]  W. Mcbride,et al.  A Novel Method of 18F Radiolabeling for PET , 2009, Journal of Nuclear Medicine.

[7]  Matthias Glaser,et al.  Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.

[8]  W. Cai,et al.  64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor αvβ3 Integrin Expression , 2007, Journal of Nuclear Medicine.

[9]  W. Oyen,et al.  Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Horst Kessler,et al.  Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.

[11]  M. Schwaiger,et al.  PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  M. Schwaiger,et al.  Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Horst Kessler,et al.  Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.

[14]  Horst Kessler,et al.  Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  W. Oyen,et al.  Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. , 2002, Cancer biotherapy & radiopharmaceuticals.

[16]  J Nucl Med , 2010 .

[17]  W. Mcbride,et al.  A Novel Method of 18 F Radiolabeling for PET , 2009 .

[18]  W. Oyen,et al.  Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. , 2007, European journal of nuclear medicine and molecular imaging.

[19]  W. Cai,et al.  (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Schwaiger,et al.  Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Schwaiger,et al.  Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation , 2004 .